A prior study has indicated that TGM2, which is an M2 marker, is downregulated in NAFLD to an extent correlating with the increased levels of the M1 markers IL-1β and IL-6, thus aggravating hepatic inflammation and liver injury in NAFLD 15. This evidence concerns the gene TGM2 and metabolic dysfunction-associated steatotic liver disease.